Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report

Go Makimoto; Atsushi Shimonishi; Kadoaki Ohashi; Kiichiro Ninomiya; Hisao Higo; Yuka Kato; Masanori Fujii; Toshio Kubo; Eiki Ichihara; Katsuyuki Hotta; Masahiro Tabata; Yoshinobu Maeda; Katsuyuki Kiura

doi:10.1159/000524326

Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report

Case Rep Oncol. 2022 May 5;15(2):494-498. doi: 10.1159/000524326. eCollection 2022 May-Aug.

Authors

Affiliations

¹ Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
² Division of Hospital-based Cancer Registry, Okayama University Hospital, Okayama, Japan.
³ Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
⁴ Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan.
⁵ Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.

Abstract

Tepotinib, the novel MET-tyrosine kinase inhibitor, shows an antitumor effect for patients with non-small-cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation. In January 2022, the AmoyDx® Pan Lung Cancer polymerase chain reaction Panel (AmoyDx® panel), which had a shorter turnaround time than the conventional test, was launched in Japan as a tepotinib companion test. We report a patient with an advanced MET-mutant NSCLC promptly diagnosed using the AmoyDx® panel and successfully treated with tepotinib. Although the patient's performance status (PS) worsened due to the rapid tumor progression and lung abscess formation, the tumor shrank immediately after tepotinib treatment with marked PS improvement.

Keywords: MET; Non-small-cell lung cancer; Tepotinib.

Publication types

Case Reports